(Q38177048)

30 August 2017

Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors (English)

1 reference

30 August 2017

0 references

Jolanta M Siller-Matula

1

1 reference

30 August 2017

D Trenk

2

1 reference

30 August 2017

S Krähenbühl

3

1 reference

30 August 2017

A D Michelson

4

1 reference

30 August 2017

G Delle-Karth

5

1 reference

30 August 2017

1 January 2014

1 reference

Journal of Thrombosis and Haemostasis

30 August 2017

1 reference

30 August 2017

12

1 reference

30 August 2017

1

1 reference

30 August 2017

2-13

1 reference

Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases

30 August 2017

1 reference

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

Genetic variability in response to clopidogrel therapy: clinical implications

21 January 2018

1 reference

Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro

21 January 2018

1 reference

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

21 January 2018

1 reference

Pharmacokinetic basis of the antiplatelet action of prasugrel

21 January 2018

1 reference

The disposition of prasugrel, a novel thienopyridine, in humans.

21 January 2018

1 reference

Ticagrelor: from discovery to Phase III clinical trial

21 January 2018

1 reference

Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects

21 January 2018

1 reference

Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications

21 January 2018

1 reference

Membrane transporters in drug development

21 January 2018

1 reference

Differential induction of various carboxylesterases by certain polycyclic aromatic hydrocarbons in the rat

21 January 2018

1 reference

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

21 January 2018

1 reference

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme

21 January 2018

1 reference

CYP2D6 in the metabolism of opioids for mild to moderate pain

21 January 2018

1 reference

Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development

21 January 2018

1 reference

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

21 January 2018

1 reference

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in plat

21 January 2018

1 reference

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

21 January 2018

1 reference

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.

21 January 2018

1 reference

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel

21 January 2018

1 reference

The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.

21 January 2018

1 reference

Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.

21 January 2018

1 reference

Calcium-Channel Blockers Do Not Alter the Clinical Efficacy of Clopidogrel After Myocardial Infarction

21 January 2018

1 reference

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study

21 January 2018

1 reference

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

21 January 2018

1 reference

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

21 January 2018

1 reference

Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome

21 January 2018

1 reference

A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention

21 January 2018

1 reference

Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel

21 January 2018

1 reference

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

21 January 2018

1 reference

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study

21 January 2018

1 reference

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

21 January 2018

1 reference

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.

21 January 2018

1 reference

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers

21 January 2018

1 reference

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.

21 January 2018

1 reference

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel

21 January 2018

1 reference

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

Clopidogrel and calcium-channel antagonists: another drug-drug interaction for the ever-wary clinician?

21 January 2018

1 reference

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

21 January 2018

1 reference

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

21 January 2018

1 reference

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

21 January 2018

1 reference

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JTH.12445

1 reference

30 August 2017

1 reference